These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 11743941)

  • 41. Neurotensin: an endogenous antipsychotic?
    Kinkead B; Nemeroff CB
    Curr Opin Pharmacol; 2002 Feb; 2(1):99-103. PubMed ID: 11786316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neurotensin-deficient mice show altered responses to antipsychotic drugs.
    Dobner PR; Fadel J; Deitemeyer N; Carraway RE; Deutch AY
    Proc Natl Acad Sci U S A; 2001 Jul; 98(14):8048-53. PubMed ID: 11427716
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of acute and subchronic d-amphetamine on ventral striatal concentrations of neurotensin and neuropeptide Y in rats treated with antipsychotic drugs.
    Gruber SH; Nomikos GG; Mathé AA
    Eur Neuropsychopharmacol; 2006 Dec; 16(8):592-600. PubMed ID: 16524702
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serotonin in antipsychotic drugs action.
    Amato D
    Behav Brain Res; 2015 Jan; 277():125-35. PubMed ID: 25078293
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of the stereoisomers of butaclamol on neurotensin content in discrete regions of the rat brain.
    Bissette G; Dauer WT; Kilts CD; O'Connor L; Nemeroff CB
    Neuropsychopharmacology; 1988 Dec; 1(4):329-35. PubMed ID: 2472151
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuropeptide Receptor Ligands for the Treatment of Schizophrenia: Focus on Neurotensin and Tachykinins.
    Griebel G
    Curr Pharm Des; 2015; 21(26):3807-12. PubMed ID: 26044977
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacological specificity of the increase in neurotensin concentrations after antipsychotic drug treatment.
    Myers B; Levant B; Bissette G; Nemeroff CB
    Brain Res; 1992 Mar; 575(2):325-8. PubMed ID: 1349254
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neurotensin: A role in substance use disorder?
    Ferraro L; Tiozzo Fasiolo L; Beggiato S; Borelli AC; Pomierny-Chamiolo L; Frankowska M; Antonelli T; Tomasini MC; Fuxe K; Filip M
    J Psychopharmacol; 2016 Feb; 30(2):112-27. PubMed ID: 26755548
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neurotensin, antipsychotic drugs, and schizophrenia. Basic and clinical studies.
    Nemeroff CB; Levant B; Myers B; Bissette G
    Ann N Y Acad Sci; 1992; 668():146-56. PubMed ID: 1361110
    [No Abstract]   [Full Text] [Related]  

  • 50. Interactions of neurotensin with dopamine-containing neurons in the central nervous system.
    Ervin GN; Nemeroff CB
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12 Suppl():S53-69. PubMed ID: 3074341
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Brain neurotensin, psychostimulants, and stress--emphasis on neuroanatomical substrates.
    Geisler S; Bérod A; Zahm DS; Rostène W
    Peptides; 2006 Oct; 27(10):2364-84. PubMed ID: 16934369
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative sequencing of the proneurotensin gene and association studies in schizophrenia.
    Austin J; Hoogendoorn B; Buckland P; Speight G; Cardno A; Bowen T; Williams N; Spurlock G; Sanders R; Jones L; Murphy K; McCarthy G; McGuffin P; Owen MJ; O'Donovan MC
    Mol Psychiatry; 2000 Mar; 5(2):208-12. PubMed ID: 10822351
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of chronic infusion of neurotensin and a neurotensin NT1 selective analogue PD149163 on amphetamine-induced hyperlocomotion.
    Norman C; Beckett SR; Spicer CH; Ashton D; Langlois X; Bennett GW
    J Psychopharmacol; 2008 May; 22(3):300-7. PubMed ID: 18208905
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antipsychotic drug-like facilitation of latent inhibition by a brain-penetrating neurotensin-1 receptor agonist.
    Feifel D; Shilling PD; Fazlinejad AA; Melendez G
    J Psychopharmacol; 2016 Mar; 30(3):312-7. PubMed ID: 26783230
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The electrophysiological actions of neurotensin in the central nervous system.
    Stowe ZN; Nemeroff CB
    Life Sci; 1991; 49(14):987-1002. PubMed ID: 1890928
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neurotensin agonists: possible drugs for treatment of psychostimulant abuse.
    Richelson E; Boules M; Fredrickson P
    Life Sci; 2003 Jun; 73(6):679-90. PubMed ID: 12801589
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential effects of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions.
    Gygi SP; Gibb JW; Hanson GR
    J Pharmacol Exp Ther; 1994 Jul; 270(1):192-7. PubMed ID: 7913495
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sex- and estrous cycle-related differences in the effects of acute antipsychotic drug administration on neurotensin-containing neurons in the rat brain.
    Kinkead B; Lorch SM; Owens MJ; Nemeroff CB
    J Pharmacol Exp Ther; 2000 Oct; 295(1):205-11. PubMed ID: 10991980
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Endogenous neurotensin attenuates dopamine-dependent locomotion and stereotypy.
    Chartoff EH; Szczypka MS; Palmiter RD; Dorsa DM
    Brain Res; 2004 Oct; 1022(1-2):71-80. PubMed ID: 15353215
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The electrophysiological effects of neurotensin on spontaneously active neurons in the nucleus accumbens: an in vivo study.
    Stowe ZN; Landry JC; Tang Z; Owens MJ; Kinkead B; Nemeroff CB
    Synapse; 2005 Dec; 58(3):165-72. PubMed ID: 16108007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.